Alembic Limited, with an established presence in the Indian pharma

industry has a proud, historical track record going back one hundred
years. With a turnover in excess of Rs1000 crores today, Alembic
Limited is one of India’s leading integrated pharmaceutical companies.
We continue to enjoy leadership positions in antibiotics, anti-infective,
anti-cough and also have significant worldwide presence in specialty
therapeutic areas such as cardiology, neurology, diabetology, etc. We
have also plans for expansion in Ophthalmic etc.

Alembic’s manufacturing facilities are at Vadodara, Panelav in Gujarat,

and Baddi in Himachal Pradesh. The facilities are approved by the US
FDA, EDQM, TGA, MHRA, and MCC.

Alembic Research Center (ARC) a world-class research organization

provides a comprehensive range of services in the areas of synthetic
chemistry, formulations, NDDS, as also preclinical pharmacology,
bioequivalence / bioanalytical studies, etc. ARC, designed to state-of-
the-art GLP standards, is spread over an area of 120,000 sq ft,
manned by over 300 scientists working on latest technology and
systems.

Our current employee strength is in excess of 4500 across the country.

A continuously expanding organization, we invite dynamic, result-
oriented professionals to join us across various functions

Designation Marketing Executive

Job Face of the company for customers. Implement
Description Company strategy. Implement of product promotion
strategy. Generate prescriptions in line with the
business strategy. Maintain and develop relations
with existing and new customers through appropriate
propositions and sales methods. Optimize quality of
service, business growth, and customer satisfaction.
Desired Profile Freshers with Qualification - BSc / MSc / BPharm .

Age - Upto 25 years ( For Freshers )

- Upto 27 years ( For candidates having minimum

1 year

of Medical Representative Experience )

Experience 1 - 2 Years
Industry Type Pharma/ Biotech/Clinical Research
Role Medical Rep.
Functional Sales, BD
Area
Education UG - B.Pharma - Pharmacy,B.Sc - Any
Specialization,BVSC - Veterinary Science
PG - Any PG Course - Any Specialization
Compensation: Best in the Industry
Location Jamshedpur, Ranchi, Silchar,
Motihari Saharsha , Sahebganj
Keywords Medical Repsentative
Contact Mr. Anupam Roy - ZSM - East
Alembic Ltd
Telephone 09339143789
Website http://www.alembic-india.com
Job Posted 10 Dec
Reference Mail to mx.tapash.dey@alembic.co.in;
mx.anupam.roy@alembic.co.in

.: DOMESTIC FORMULATIONS

Our extensive range of Finished Dosage Forms cover every aspect of human life. We
possess expertise in the manufacture of high volume Finished Dosage Forms and
effectively control their release profile. This expertise is in the field of sterile as well as
non-sterile dosage forms. Alembic has commissioned a solid Oral dosage facility
approved by MCC South Africa and MHRA UK

Find out more about :

Branded Formulations
Antibiotics & Anti bacterials Cough & Cold
Antihistamines NSAIDS
Oral Hypoglycemic Herbals & Nutraceuticals
Cardiovascular Others

For Business Inquiries please click here

Generics
At present we have 90 brands with extension in various forms covering the therapeutic
segments of Antibiotic, Cough & cold, NSAID, B-complex, C.V.Drugs etc.

Therapeutic segments Antiallergic

Anticold Preparation Anthelminitic
Antimalarials Antimicrobials
Antioxidants Antipyretics
Antiseptic Antispasmodic
Antiulcerants Cardiovascular Drugs
Corticosteroids Cough Preparations
Enzyme Preparation Mucolytics & Proteolytics
Nsaids Tranquiliser
Vitamin Preparations Others
.: BRANDED FORMULATIONS - GYNAECOLOGICAL

For Business Inquiries please click here

Antibiotics & Antibacterials Herbals & Nutraceuticals

Cough & Cold Cardiovascular
Antihistamines Gynaecological
NSAIDS Gastrointestial
Oral Hypoglycemic Ophthalmic Preparations
Others
GYNAECOLOGICAL PRODUCTS
Crina 20
Ethinyl Estradiol 20 mcg & Drospirenone Bottle 20 Tabs
3 mg
CYCLOSET
Tranexamic acid 500 mg + Mefenamic Strip 6 Tabs
acid 250 mg tab
FOLINAL
Folic Acid 5 mg Bottle 30 Tabs
FOLINAL PLUS
Folic Acid 5 mg + Methylcobalamin 750 Strip 10 Tabs
mcg + Pyridoxine 10 mg
FOLIRIPE
Letrozole 2.5 mg tab
GESTOFIT
Natural Micronised Progesterone Strips 10 Tabs
Natural Micronised Progesteron Injection 2ml/4ml
HARMONI
Cyperoterone Acetate 2 mg + Ethinyl Strips 21 tabs
estradiol 0.035 mg tab
LACTONIC
Satavari (15 gm/100gm), Sowa, Palak, Bottle 200 gms
Safed Jeera
MEGA MOM
Whey Protein Isolate with DHA 80 mg & Bottle 200 gms
GLA 25 mg per 100 gm
OVIGYN
HCG 2000, 5000, 10000 IU Bottle 200 gms
RICHAR-XT
Ferrous Ascorbate 100 mg + Folic Acid strips 10 gms
1.5 mg tab
RICHAR-XT - Injection
Iron Sucrose 100 mg/5 ml Injection 5 ml
Vehycal
Calcium Aspartate anhydrous 560 mg tab Strips 10 Tabs
equivalent to 73 mg elemental calcium

BUSINESS OPPORTUNITIES

We are always looking for collaborative business opportunities in the

areas of Marketing, Distribution,Co-development, Research, Contract
Manufacturing & Joint Ventures. If you are interested in exploring
possibilities in any of these areas please click on appropriate partner
areas to send us your query.

Name *

Designation *

Company *
Mailing Address
*

City *
Zip/Postal Code
*
Country *

Telephone *

Fax
E-mail address
*
Website

What kind of Business Partnership are you looking for? (Please

check the appropriate box)
Co-
Marketing Distribution Research
development
Contract Joint Other
Manufacturing Venture enquiries

News &
WELCOME TO ARC
Events
ARC is a rapidly growing contract research services
organization providing a wide range of services to global
research based pharmaceutical and biotech companies.

The services provided are in the domains of Chemistry,

Formulations, Pre-clinical Bioequivalence / Bioanalytical
studies.

ARC has a multidisciplinary team based approach to

the various challenges posed by the drug discovery
industry.

We trust in integrity, confidentiality and quality of

our research solutions and can be a valued partner
to your Research team and drug discovery process.

ARC PROFILE
Based at Vadodara, India (250 miles
north of Mumbai) ARC is the research
and development division of Alembic
Limited, one of India's reputed and
well-established integrated-pharma
company.

Objective:
ARC
 Offers value-added solutions to increase the efficiency of global
pharmaceutical and biotech
companies’ R&D efforts.
Through partnering complements the intense R&D efforts of these
companies’ to discover, develop & manufacture quality products
with greater speed, at reduced costs and total confidentiality.

Since its inception in the year 2003, ARC has gained a reputation of a
well-known contract research organization providing good-quality and
wide range of services.

Today, we can boast of a number of reputed global companies on our

list of clients collaborating with us in the various domains of services
we offer..

With a state-of-the-art research infrastructure spread over an area of

120,000 square feet, ARC’s facilities have been designed according to
GLP standards.

It houses all the major analytical instruments to complement the

research work of its scientists. ARC has a rich-pool of scientists that
bring together over 750 man-years of rich and varied experience
spanning across all domains of services.

ARC ADVANTAGES

Since we possess the 10 commandments of Partnering…

Enviable track record
Protecting partner’s interest
Width of services
World class research infrastructure
Well-defined processes
Highly talented research team
Superior project management
Scientific advisory board
 Proactive HR policies
Credible Financial & Corporate Governance Track Record

Enviable Track Record

ARC today has sizeable number of multi-year FTE based research contracts and projects in
place with reputed MNCs. This showcases ARC’s ability to handle any complex project of
MNCs, with specific reference to

Technical competence
Infrastructure
Project management abilities and
Effective delivery through reliability, confidentiality and customer delight

Protecting Partner’s Interests

Protecting its partner’s interests is the primary responsibility of ARC. With India being a WTO
member, we ensure total commitment and compliance to harmonized patent laws. Any
product related development would be the intellectual property of our partner. Our scientists
working for the clients are also bound by intellectual property confidentiality agreements.

Width of Services

ARC offers you a wide and complete range of services ranging from Chemistry to
Formulation development and Bioequivalence studies. Our continuous efforts are to provide
our clients a complete solution and act as a single point shop!

World-class research infrastructure

ARC has all the requisite facilities for synthetic chemistry, analytical, pharmaceutical
research The laboratories are well equipped with modern equipment including NMR (300
MHz), LCMS/MS-Q trap model, HPLC, prep HPLC, flash chromatographs, GC, DSC,
Chromatotron, NeoCota, Conta blender, Luminometer, Fluorimeter, UV/VIS
Spectrophotometer, Ultralow freezers etc. along with Kilo lab & pilot manufcturing plant
(upto 100 Kg levels).
ARC also houses a modern information center spread over an area of 2,500 sq. ft. with a
collection of over 10,000 books dedicated to pharmaceutical research. It also subscribes to
over 100 international and national journals with access to Sci-finder and STN.

Well-defined Processes

The preparation, approvals, distribution, retrieval, periodic reviews of documents is well

controlled. Well-defined documentation SOPs ensure reliability and confidentiality of data
generated.

ARC ensures data protection by having separate teams for clients and promoting a culture
wherein confidential information does not flow across them. The reporting format is
according to globally accepted or regulatory standards, aided by advanced software tools.
The safety of data transmission over internet is ensured by using data encryption software.

Highly Talented Research Team

ARC has one of the best of scientific pool (a mix of post docs & postgraduates from reputed
international & national research organizations) in the Indian pharmaceutical industry. Over
750 man-years of research experience synergise drug discovery efforts.

Superior Project Management

The project management part essentially encompasses

quote preparation & feasibility assessment,

raw materials sourcing, invoicing,
human resource utilization, task progress and slippage,
weekly summary reporting, teleconferencing and submission of final report on project
completion.

These activities are aided with use of software tools like MS-Project, SAP and ACD database.

The project manager acts as a strong interface and single point contact between its two
customers viz.

External - the clients & vendors

Internal - the scientific community, management & support services.

In addition to this, regular communication between the project team with the client is
facilitated using video-conferencing, teleconferencing, fax and internet.

Scientific Advisory Board

ARC is supported by active participation of reputed scientists and technologists who are
leaders in their respective fields and are committed to make ARC - a center of excellence.
We already have some well-renowned scientists on our advisory board.

Proactive HR Policies

ARC values the intellect of its employees by encouraging continuous up-gradation of their
knowledge base. ARC offers a congenial work atmosphere to foster self-motivation, self-
assessment & self-confidence.

We also have a fast track recruitment process in place to cater to the changing and
increasing demands of our clients in a short lead-time. We are also actively promoting
scientific creativity to get access to new emerging talent, and have tied up with leading
national institutes and universities in this regard.

Credible Financial & Corporate Governance Track Record

Alembic’s past trust and credibility in Indian financial and business circles gives ARC a
dependable and reliable partner image.

Thus ARC possesses the financial muscle for making investments on infrastructure, crucial to
our partner’s requirements. In addition to this, Alembic’s top management is fully committed
to make ARC - a world class pharmaceutical services provider organization.

ARC CHEMISTRY
Within the pharmaceutical industry, we are well known for our ability to carry out wide and safe
processes for complex molecules as well as for high pressure and temperature reactions.

We provide expertise in the early stages of drug development, whether creating a synthetic
route for a new chemical entity or optimizing an existing process. Our repertoire includes both
classical and modern organic reactions. We also possess capabilities of impurity isolation and
synthesis. The services offered under this domain are:

Synthetic organic chemistry & creating compound libraries

Process chemistry at gm to Kg levels
Custom synthesis
Impurities isolation & synthesis
Analytical chemistry services
ARC CAREERS
We share collaborative & symbiotic relationships with preferred
business partners, our employees, all of whom reflect our business
ethics, trust & transparency and quality standards.

Our focus on developing human values and potential through various

learning and developmental activities has groomed and retained talent
internally by offering promising career opportunities.

Culture, Beliefs & Values

Relations at ARC, be it hierarchical or lateral are essentially formally

informal, they are collaborative rather than being competitive. The
basis of our relationship is trust.

The environment at ARC can be defined as positive, informal and not

protocol oriented, built on mutual strengths, where every
achievement, big or small is appreciated.

We, at ARC believe in being simple, humble, and honest. We believe in

and value human dignity.
We value openness and teamwork in our interpersonal dealings. We
respect and reflect a mindset that is Pro Change. That is the basis of
our historical existence and sustained progress.

In our quest to be a global research services provider, ARC is keen to

associate with talented, high performing people. ARC prides itself for a
rich talent base that can successfully propel the company to even
greater heights in an increasingly competitive global R & D
environment.

ARC IN NEWS

Alembic Starts Construction of new R&D center

(Date: 2'nd June'03The civil work of the new R&D Centre at Vadodara,
Gujarat has commenced on the 2nd of june 2003. The new Research
Centre would offer state-of-the-art research infrastructure having a
carpet area of 80,000 square feet.
The facility would consist of Chemistry, Analytical and Biological
Laboratories. An Animal House facility for the pharmacological and
toxicological studies in rodents is also being created.

The R&D Center would house an Information center subscribing to

latest books, international and national journals with in-house access
to Sci-finder and ST
The civil work of the new R&D Centre at Vadodara, Gujarat has
commenced on the 2nd of june 2003. The new Research Centre would
offer state-of-the-art research infrastructure having a carpet area of
80,000 square feet.

The facility would consist of Chemistry, Analytical and Biological

Laboratories. An Animal House facility for

Alembic, a Baroda-based pharma company, has scripted a major

thrust on contract research as part of its strategy to increase its
presence in the segment.
Alembic has entered a contract research agreement with Chiron
Corporation, a research-based pharmaceuticals company
headquartered at Emeryville, California. The agreement, which has
been signed between these two companies, will seek to use the
expertise offered by Alembic in the field of heterocyclic chemistry.
Based on Alembic's research, Chiron will develop new drugs for
different therapeutic segments.

"Besides Chiron Corporation, we are also talking to a couple of foreign

companies for contract research," HT Patel, senior VP, Alembic, told
ET. The company seeks to boost its revenues by focusing on contract
research and by utilising its R&D base, Mr Patel said.

It may be pointed out that like multinational IT companies, many

foreign companies have started using the R&D base of Indian
pharmaceutical companies to develop new drugs. As foreign
companies have started outsourcing molecules from Indian companies,
the market size of contract research is growing at a rate of 100%, a
pharma analyst said. At present, market size of contract research in
the country is around Rs 100 crore and as many 18 companies are
engaged in contract research.

Alembic, which has core concentration on bulk drugs and formation for
human health and veterinary segments, is also restructuring its
business to focus on three strategic areas - nutraceuticals,
antidiabetics and antibiotics - which will be the key drivers for growth
in the coming years. The company has recently set up a new division
for cardiovascular and diabetic drugs as well.
The company is planning to launch its new drugs in these segments
and is targeting the highly regulative markets like US and Europe for
its new drugs.

Alembic enters into contract research agreement with Chiron

Corp - California
Source: Economic Times (Date: 5'th Nov' 02)

Alembic Ltd has informed BSE that the company has entered into
contract research agreement with Chiron Corporation, a Research
based pharmaceutical company headquartered in Emeryville,
California.

Chiron applies its advanced understanding of the biology of cancer and

infectious disease to develop products from its flatforms in proteins,
small molecules and vaccines. The multi year agreement will seek to
utilize the expertise offered by company in the field of Heterocyclic
chemistry.

Alembic and Chiron enter into a research pact

Source: EconomicTimes (Date: 4'th Nov'02)

Mumbai : Alembic has tied up with Chiron Corporation of the US for

contract research. The multi-year deal seek to use expertise offered by
the US firm in the field of heterocyclic chemistry. Chiron Corporation,
applies its advanced understanding of the biology of cancer and other
infectious diseases to develop products from its flatforms in proteins,
small molecules and vaccines.

Alembic`s research and development team mainly targets on microbial

research, reverse engineering, process improvement, new chemical
entities and development of new formulations. The company has been
spending around 2-3 per cent of its turnover on research and
development efforts. Alembic spent around Rs 14.41 crore, or 2.31 per
cent of its turnover, on R&D.

The company develops non-infringing patentable routes of

manufacturing drugs, whose existing patents are set to expire in the
near future. Alembic also plans to do substantial research work in the
area of new chemical entities to find potent macrolides. Similar project
has already been initiated in association with the National Chemicals
Laboratory

The civil work of the new R&D Centre at Vadodara, Gujarat has
commenced on the 2nd of june 2003. The new Research Centre would
offer state-of-the-art research infrastructure having a carpet area of
80,000 square feet.

The facility would consist of Chemistry, Analytical and Biological

Laboratories. An Animal House facility for the pharmacological and
toxicological studies in rodents is also being created.

The R&D Center would house an Information center subscribing to

latest books, international and national journals with in-house access
to Sci-finder and STN.

ALEMBIC BETS BIG ON CONTRACT RESEARCH

Source: Economic Times (Date:30'th April' 03)

Alembic, a Baroda-based pharma company, has scripted a major

thrust on contract research as part of its strategy to increase its
presence in the segment.
Alembic has entered a contract research agreement with Chiron
Corporation, a research-based pharmaceuticals company
headquartered at Emeryville, California. The agreement, which has
been signed between these two companies, will seek to use the
expertise offered by Alembic in the field of heterocyclic chemistry.
Based on Alembic's research, Chiron will develop new drugs for
different therapeutic segments.
"Besides Chiron Corporation, we are also talking to a couple of foreign
companies for contract research," HT Patel, senior VP, Alembic, told
ET. The company seeks to boost its revenues by focusing on contract
research and by utilising its R&D base, Mr Patel said.

It may be pointed out that like multinational IT companies, many

foreign companies have started using the R&D base of Indian
pharmaceutical companies to develop new drugs. As foreign
companies have started outsourcing molecules from Indian companies,
the market size of contract research is growing at a rate of 100%, a
pharma analyst said. At present, market size of contract research in
the country is around Rs 100 crore and as many 18 companies are
engaged in contract research.

Alembic, which has core concentration on bulk drugs and formation for
human health and veterinary segments, is also restructuring its
business to focus on three strategic areas - nutraceuticals,
antidiabetics and antibiotics - which will be the key drivers for growth
in the coming years. The company has recently set up a new division
for cardiovascular and diabetic drugs as well.
The company is planning to launch its new drugs in these segments
and is targeting the highly regulative markets like US and Europe for
its new drugs.

Alembic enters into contract research agreement with Chiron

Corp - California
Source: Economic Times (Date: 5'th Nov' 02)

Alembic Ltd has informed BSE that the company has entered into
contract research agreement with Chiron Corporation, a Research
based pharmaceutical company headquartered in Emeryville,
California.

Chiron applies its advanced understanding of the biology of cancer and

infectious disease to develop products from its flatforms in proteins,
small molecules and vaccines. The multi year agreement will seek to
utilize the expertise offered by company in the field of Heterocyclic
chemistry.
Alembic and Chiron enter into a research pact
Source: EconomicTimes (Date: 4'th Nov'02)

Mumbai : Alembic has tied up with Chiron Corporation of the US for

contract research. The multi-year deal seek to use expertise offered by
the US firm in the field of heterocyclic chemistry. Chiron Corporation,
applies its advanced understanding of the biology of cancer and other
infectious diseases to develop products from its flatforms in proteins,
small molecules and vaccines.

Alembic`s research and development team mainly targets on microbial

research, reverse engineering, process improvement, new chemical
entities and development of new formulations. The company has been
spending around 2-3 per cent of its turnover on research and
development efforts. Alembic spent around Rs 14.41 crore, or 2.31 per
cent of its turnover, on R&D.

The company develops non-infringing patentable routes of

manufacturing drugs, whose existing patents are set to expire in the
near future. Alembic also plans to do substantial research work in the
area of new chemical entities to find potent macrolides. Similar project
has already been initiated in association with the National Chemicals
Laboratory

The 101-year-old Alembic, India's oldest pharmaceutical company, has chalked

out an aggressive expansion plan to double its turnover within 2 to 3 years by
foraying into the regulated markets of the US and Europe as well as contract
manufacturing.

The Rs 1,027-crore company has filed 13 abbreviated new drug applications

(ANDAs) and 22 drug master files (DMFs) with the US Food and Drug
Administration (FDA) and regulatory agencies in Europe for supply of
formulations and active pharmaceutical ingredients (APIs).
Some of the ANDAs challenge innovator patents and the company's strategy will
be to partner with established companies in the US and Europe for marketing
formulations, said Pranav Amin, director, Alembic.

"I feel we are about ten years late to enter the regulated markets, but will file
about 10-12 ANDAs every year to tap potential in the generic markets of the US
and Europe. We will also tap Latin America and Africa," he said.

Alembic's plan is to follow the low-risk and less-expensive model of roping in

strategic alliances with major companies with presence in the US and Europe for
supplying drugs, similar to the business model of drug major Cipla, instead of
creating own front-ends through greenfield projects and expensive acquisitions in
various geographies.

Currently, exports to non-regulated markets contribute only 20 per cent of the

turnover and plans are afoot to improve this to a ratio of 50:50 in coming years.
Alembic was talking to several multinational and domestic companies to rope in
alliances, he said.

"Now large retail chains in the US are looking at second-level Indian companies
with quality manufacturing facilities for direct drug supplies and we will try to
capitalise that opportunity. Contract manufacturing for the big pharma is also
another major focus area," said Pranav Amin, the eldest son of Chirayu Amin, the
chairman and managing director of Alembic.

Alembic has already signed a three-year contract manufacturing agreement with

a multinational company to supply APIs, which will fetch it $25-30 million
annually.

It also licensed a novel drug delivery system for the extended release version of
Keppra (levetiracetam), Belgian drug major UCB's leading epilepsy drug.

Alembic will benefit with milestone payments of $11 million and low to medium
single-digit royalties on worldwide sales of the new Keppra product, which will
soon enter the market.

Commenting on the domestic market, Pranav Amin said the company has
restructured the domestic business, with eight marketing divisions, instead of the
earlier five divisions, to focus on acute, chronic and other speciality products.

The domestic marketing team has shifted to Mumbai from Vadodara, the home of
Alembic. The company recruited 600 medical representatives alone during the
last quarter to have a field force of 2,800.
He said focus in the domestic market will be on creating more brands, especially
in acute and speciality segments, to maintain an average growth rate of over 15
per cent every year.

Alembic, the market leader in anti-infective segment (macrolides), has brands

such as Azithral (Rs 60-crore sales) Althrocin (Rs 72.5 crore) and Roxid (Rs 62
crore), which help control about 38 per cent of the domestic market for anti-
infectives.

The acquisition of Dabur's non-oncology business during the last year has helped
add about 23 products to the basket, he said.

Alembic seeks allies in US to double sales

The 101-year-old Alembic, India's oldest pharmaceutical company, has chalked

out an aggressive expansion plan to double its turnover within 2 to 3 years by
foraying into the regulated markets of the US and Europe as well as contract
manufacturing.

The Rs 1,027-crore company has filed 13 abbreviated new drug applications

(ANDAs) and 22 drug master files (DMFs) with the US Food and Drug
Administration (FDA) and regulatory agencies in Europe for supply of
formulations and active pharmaceutical ingredients (APIs).

Some of the ANDAs challenge innovator patents and the company's strategy will
be to partner with established companies in the US and Europe for marketing
formulations, said Pranav Amin, director, Alembic.

"I feel we are about ten years late to enter the regulated markets, but will file
about 10-12 ANDAs every year to tap potential in the generic markets of the US
and Europe. We will also tap Latin America and Africa," he said.

Alembic's plan is to follow the low-risk and less-expensive model of roping in

strategic alliances with major companies with presence in the US and Europe for
supplying drugs, similar to the business model of drug major Cipla, instead of
creating own front-ends through greenfield projects and expensive acquisitions in
various geographies.

Currently, exports to non-regulated markets contribute only 20 per cent of the

turnover and plans are afoot to improve this to a ratio of 50:50 in coming years.
Alembic was talking to several multinational and domestic companies to rope in
alliances, he said.
"Now large retail chains in the US are looking at second-level Indian companies
with quality manufacturing facilities for direct drug supplies and we will try to
capitalise that opportunity. Contract manufacturing for the big pharma is also
another major focus area," said Pranav Amin, the eldest son of Chirayu Amin, the
chairman and managing director of Alembic.

Alembic has already signed a three-year contract manufacturing agreement with

a multinational company to supply APIs, which will fetch it $25-30 million
annually.

It also licensed a novel drug delivery system for the extended release version of
Keppra (levetiracetam), Belgian drug major UCB's leading epilepsy drug.

Alembic will benefit with milestone payments of $11 million and low to medium
single-digit royalties on worldwide sales of the new Keppra product, which will
soon enter the market.

Commenting on the domestic market, Pranav Amin said the company has
restructured the domestic business, with eight marketing divisions, instead of the
earlier five divisions, to focus on acute, chronic and other speciality products.

The domestic marketing team has shifted to Mumbai from Vadodara, the home of
Alembic. The company recruited 600 medical representatives alone during the
last quarter to have a field force of 2,800.

He said focus in the domestic market will be on creating more brands, especially
in acute and speciality segments, to maintain an average growth rate of over 15
per cent every year.

Alembic, the market leader in anti-infective segment (macrolides), has brands

such as Azithral (Rs 60-crore sales) Althrocin (Rs 72.5 crore) and Roxid (Rs 62
crore), which help control about 38 per cent of the domestic market for anti-
infectives.

Alembic launching 7 new products

Vadodara April 13 The Vadodara-based pharma company Alembic Ltd

is set to launch several new products and expects to enter the $200-
million formulations spectrum as a future growth strategy in the
overseas market in the next couple of years.
The century-old Alembic with a basket of 200 products is now actively
eyeing the $200-million spectrum in branded formulations business or
API. It is also set to launch seven new products apart from the 24 it
recently acquired from Dabur.

Plans are afoot to celebrate Alembic's centenary this year, Chairman

and Managing Director, Mr Chirayu Amin, told Business Line here.

Besides, it is putting in place a new marketing strategy of its popular

cough syrup Glycodin whose sales have shown a downward trend in
the recent past.

Announcing completion of acquisition of the entire non-oncology

formulation business of Dabur Pharma Ltd with 24 brands for a
consideration of Rs 159 crore, Mr Amin, said that the company may try
to reallocate its assets for financing the recent take-over. Alembic Ltd
and Alembic Glass own about 130 acres each in Vadodara. "We
created debt to finance Rs 159 crore and borrowed money. We have
good accruals and we may unlock our assets in a couple of years," he
told reporters.

The acquired product mix had a turnover of Rs 75 crore in the last

fiscal, which Alembic expects to increase to Rs 100 crore this year and
double in the next three to four years.

Alembic, whose turnover was nearly Rs 700 crore also expects to

increase it to Rs 1,000 crore next year. "We expect our bottomline
from the acquisition to be more than 25 per cent and operating margin
Rs 200 crore."

In the next four years, the company expected to equalise its revenue
from domestic and foreign sales from the current 75 per cent and 25
per cent, respectively.

Mr Amin pointed out that most brands Alembic acquired from Dabur
are in the high growth lifestyle therapeutic segments of cardiology,
diabetology and gynaecology. Alembic has created a new marketing
arm, named "Summit," to cater to the needs of these speciality
segments. It is already the largest player in the Macrolides (anti-
infective) segment of drugs and is now set to increase market share in
the lifestyle segment as well.

Article: Alembic plans to set up its own SEZ.

Alembic plans to set up its own SEZ
Vadodara, Mar 27 (PTI) Alembic, the oldest pharmaceutical company in
the country, has decided to set up its own Special Economic Zone
(SEZ) dedicated to the pharma sector, its Chairman and Managing
Director Chirayu Amin said today.

The land for the proposed SEZ is located at Kavi and Nahar village on
the Mahisagar Tidal sanctuary, about 60 kms from here, Amin told PTI.

This will be a single sector SEZ focussing on meeting the requirments

of the pharmaceutical industry for the entire spectrum of naturally
Derived/Biologically-developed/ Semi-Synthetically-
developed/Synthetically-developed drugs and their ...

Alembic POS goes live!

Max is an old and true friend, and I was delighted to get him set up with a good starter
site.

Max is also a keen geek, so I decided against putting a layer of abstraction, such as a CMS
or blogging platform, between him and his code. Instead I tried to build good code. I
started with a variation on the Blueprint CSS framework, to reset browser styles to a
consistent layout, simplify inner-page styling, and get that ever-so-elegant vertical
alignment, the “je-ne-sais-quoi” that makes a site look incredibly more pleasant and
professional.

The logo is an old friend. It was designed in 1992 by Todd Steigerwald, an amazingly
talented designer and illustrator, and close friend to both Max and me. Max has obtained
the rights to this logo for his new venture, and it was a treat to get to work with it. I
added a bit of light and shadow to it, but kept even the original typeface, which I think
still works. We sure enjoyed character stretching in the late eighties and early nineties!

In terms of marketing strategy, we went ahead with “local matters”, since that is
Alembic’s stronger differentiator for prospects and new clients, until they get to know
Max. A picture of Red Rocks national park would click with our target market, and it
gave us a warm, vibrant color scheme, miles away from corporate blue.

In the end, I’ve given Max a clean base to start from. Thanks to Blueprint, the html code
stays very light and very discoverable, perfect for hand-editing. And the visual design
and brand identity should give him an edge on his drab and messy competitio .

Alembic in talks for acquiring domestic ophthalmic company

Ophthalmics is a niche segment and unlike other categories in the
domestic pharmaceutical market which are crowded.

Mumbai: Alembic Ltd, the maker of the cough preparation Glycodin which
acquired part of Dabur’s pharmaceuticals business earlier this year is now
eyeing a domestic maker of ophthalmic products as part of its inorganic
growth strategy. “We plan to enter the ophthalmic segment through an
acquisition in this space and we are in discussions to buy a company. The
size of the deal could be about Rs100 crore,” said Chirayu R. Amin, chairman
and managing director of Alembic. He declined to divulge further details.

Alembic ended 2006-07 with Rs700 crore in net sales.

The company said its target would have expertise in manufacturing

ophthalmic products. “We can build on these technologies to grow our
presence in the ophthalmic segment, both in the domestic market as well as
in the international markets,” said Pradeep Rane, president-formulations
business, Alembic.

Ophthalmics is a niche segment and unlike other categories in the domestic

pharmaceutical market which are crowded, few companies such as Allergan
India Pvt. Ltd and Cipla Ltd have a significant presence in it.

The domestic ophthalmology market is currently valued at around Rs400

crore and is growing at over 15%.

Alembic said it was also looking at other “high growth” segments. “We are
also interested in companies that have a product portfolio focusing on
gynaecology and dermatology,” said Amin. The company has not yet
identified companies in these segments and is still scouting for likely targets.

The acquisitions will help Alembic diversify its portfolio; the company
currently earns most of its revenue from anti-infective products. Alembic has
also announced the signing of an out-licensing deal with Belgian
pharmaceutical company, UCB, for proprietary technology it has developed.

Based on this technology, Alembic claims to have developed a once-a-day

formulation version of UCB’s anti-epileptic drug Keppra. It will receive
milestone payments of $11 million (Rs45.1 crore) and royalty on future
worldwide net sales of the product. Keppra had sales of €761 million in 2006.
The Alembic stock on Wednesday rose 12.53% to close at Rs65.10 on the
Bombay Stock Exchange.

Alembic sets sights on regulated markets

 Mr Atul Barman, Vice-President, Alembic Ltd, at a press conference in Mumbai on Wednesday.

MUMBAI, Oct. 16

ALEMBIC Ltd, the Baroda-based pharma company has set its eyes on the
international markets, particularly the regulated ones such as the US Europe.
The company currently has a small presence in these lucrative markets.

Says Mr Atul Barman, Vice-President, Alembic Ltd, "We are in the preparatory
stage as far as the international markets are concerned. The company has
identified two plants in Panela, near Baroda primarily for exporting to these
markets."

The company has started upgradation and expansion process in these two
manufacturing facilities. "We are hoping to get a USFDA (United States Food and
Drug Administration) approval by the end of this year," Mr Barman said.

Alembic is also scouting for potential partners in the US and Europe for
marketing and distribution of its products. "We are looking at tying up with other
companies for marketing and distribution in the generic category," he said.

The company had late last year announced a restructuring exercise in line with
recommendations by global consultants, Accenture, to increase operational
efficiency, productivity, cost rationalisation and supply-chain management.
Subsequently, Alembic formed five business units, the latest one being SynX.

SynX (or Syndrome X) unit will cater to metabolic disorders comprising central
obesity, glucose intolerance, hyperlipidemia and high blood pressure. According
to Mr Barman, the target for the first 18 months would be around Rs 25 crore.

"Initially we will be having about nine products in this segment with a team of
about 150 people. We will also be setting up a call centre for doctors in case they
need any samples of the products," he said.
The company also plans to achieve a turnover of Rs 1,800 crore in the next five
years and expects to reach a turnover figure of Rs 1,000 crore in two years.

For the year ended March 2002, the company registered net sales of Rs 560
crore and a net profit of Rs 23.5 crore.

Alembic rises on value buying

Alembic has been rising steadily in the recent past on value buying following a slew of new developments in
the company.

From a recent low of Rs 137 touched on 31 March, the Alembic stock has risen 32.51 per cent to Rs 181.55
on 9 May -- touching a 52-week high of Rs 194 . While the BSE Healthcare Index has risen 1.69 per cent in
the same period, the 30-share BSE Sensitive Index (Sensex) has lost 3.23 per cent. The average daily
volumes on the Alembic counter have risen to around 5,000 shares from 2,500 shares during this period.

In a most recent development, Alembic entered into a contract research pact with Chiron Corporation, a
research-based pharmaceutical company based in Emeryville, California, USA.

Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop
products from its platforms in proteins, small molecules and vaccines.

Earlier, Alembic said it was targeting a turnover of Rs 25 crore from its recently set up strategic business unit
SynX for the 18-month period. SynX comprises Alembic's cardio and diabetic division, which currently
accounts for Rs 6.5 crore (Rs 65 million) of the company's turnover. Alembic also said that plans are afoot
for launching seven new products under SynX in the next few months. SynX already has a portfolio of nine
products.

SynX caters to patients suffering from a condition called Syndrome X. Syndrome X is a term indicating the
association of glucose intolerance, dyslipidemia, hypertension and insulin resistance. These metabolic
abnormalities are often associated with insulin resistance.

Alembic has already dedicated a 100-member team for the division. Products that have been brought under
this division include nateglinide (Natelide), pioglitazone (Piolem), gliclazide (GLZ, GLZ Plus), glipiside
(Glipy), metformin (Forminal, Forminal SR), alprazolam (Zocam) and vitamins and minerals (Zivinal CD).

Recently, Alembic has launched a fourth generation injectable cephalosporin, Cefepime, under the brand
name of Cepime. Cepime is the only US FDA approved fourth generation cephalosporin, and its spectrum of
activity is far superior to the existing third generation cephalosporin injections like Ceftazidime, Ceftriaxone
and Cefotaxime.

Earlier, Alembic announced that it was launching a massive nationwide campaign to garner a wider reach in
the rural market for its brand Althrocin, the largest antibiotic brand in India [ Images ].
The campaign, which has been branded 'Hot Wheels', is focussing on doctors in interior areas. The
company wants to penetrate into the rural market. Alembic will put up around 250 shows in different parts of
the country, covering some 4,000 doctors. Besides northern states, the campaign will cover Madhya
Pradesh [ Images ], Maharashtra [ Images ], Andhra Pradesh, West Bengal [ Images ], Tamil Nadu and
Gujarat.

Recently, the Gujarat-based company obtained permission from the Drugs Controller General of India to
launch Cefatemet Pivoxil, an advanced antibiotic. It is the first company to launch the drug in India. Alembic
expects to clock sales of Rs 6 crore in the first year since the launch of the drug.

Alembic has also signed an agreement with an Italian pharma company, Euroresearch, to bring the latter's
products to India. The first product from Euroresearch that Alembic is in the process of launching is Gelfix
Pads. It is also exploring the possibility of introducing more products from Euroresearch to the country, and
is studying the product pipeline of the Italian firm in order to expand the scope of the alliance.

Under the recent restructuring exercise, the company also created five major strategic business units. It has
also identified co-marketing through the franchisee route as a key strategy to optimise performance.

The five SBUs -- pharma, speciality, franchisee, generics, and over-the-counter -- will promote specific
products.

In a bid to optimise the strength of its massive field force of over 1,200, the company also plans to float joint
marketing alliances with other companies.

The company has also identified six therapeutic segments -- antibacterials/antibiotics, women's health, pain
management, cough and cold preparations, anti-diabetic and cardiovascular as focus areas.

Alembic has also decided to make Mumbai [ Images ] the new hub for the marketing operations and it will be
operating its specialty and OTC divisions from this office.

In September 2002, Alembic announced that it would launch a novel drug delivery system for Nimesulide
shortly for treating pain. The NDDS has been named as Nimegesic OD and has been developed at the
company's research centre. Nimuleside is a widely used non-steroidal, anti-inflammatory drug and is
indicated for pain, fever and inflammation.

For the third quarter ended 30 December 2002, Alembic registered a 31.9 per cent rise in net profit to Rs
10.79 crore (Rs 8.18 crore) on a 2.8% fall in sales to Rs 121.49 crore (Rs 125.05 crore).

As on 31 December 2002, the promoters held 58.2 per cent stake in Alembic, while the public and
institutions held 29 per cent and 4.7 per cent, respectively.